Related Experiment Video

Updated: May 10, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

C-RAF mutations confer resistance to RAF inhibitors

Rajee Antony1, Caroline M Emery, Allison M Sawyer

  • 1Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA.

Cancer Research
|June 6, 2013
PubMed

Insights

New research identifies specific C-RAF mutations causing resistance to RAF inhibitors in melanoma. Understanding these mutations can help develop next-generation cancer drugs for BRAF-mutated cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Melanomas with BRAF(V600E) mutations initially respond to RAF and MEK inhibitors.
  • Drug resistance, often due to RAF dysregulation, is a significant clinical challenge.
  • Specific point mutations in RAF oncoproteins conferring resistance are infrequently identified.

Purpose of the Study:

  • To identify B-RAF or C-RAF mutations that confer resistance to RAF inhibitors.
  • To understand the mechanisms underlying drug resistance in BRAF-mutated melanomas.

Main Methods:

  • Utilized random mutagenesis screens to identify resistance-conferring RAF mutations.
  • Performed biochemical and pharmacologic analyses of identified C-RAF mutations.

Main Results:

  • Identified multiple C-RAF mutations, but rarely B-RAF(V600E) resistance alleles.
  • Potent C-RAF resistance mutations were found in a 14-3-3 binding site and the P loop.
  • These mutations caused paradoxical RAF kinase activity upregulation via dimerization upon RAF inhibitor exposure.

Conclusions:

  • Resistance-associated C-RAF mutations offer insights into RAF-dependent signaling.
  • Findings may help predict clinical resistance to current RAF inhibitors.
  • Knowledge gained can guide the development of next-generation inhibitors for RAF/RAS-driven cancers.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...